Meta‐analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma. BJS 2017; 104: 814-822.
Published: 18th May 2017
Authors: A. Acharya, S. R. Markar, M. H. Sodergren, G. Malietzis, A. Darzi, T. Athanasiou et al.
Periampullary cancers are uncommon malignancies, often amenable to surgery. Several studies have suggested a role for adjuvant chemotherapy and chemoradiotherapy in improving survival of patients with periampullary cancers, with variable results. The aim of this meta‐analysis was to determine the survival benefit of adjuvant therapy for periampullary cancers.
A systematic review was undertaken of literature published between 1 January 2000 and 31 December 2015 to elicit and analyse the pooled overall survival associated with the use of either adjuvant chemotherapy or chemoradiotherapy
A total of 704 titles were screened, of which 93 full‐text articles were retrieved. Fourteen full‐text articles were included in the study, six of which were
This systematic review found no associated survival benefit for adjuvant chemotherapy or chemoradiotherapy in the treatment of periampullary cancer.Read more
You may also be interested in
Authors: R. Ahola, A. Siiki, K. Vasama, M. Vornanen, J. Sand, J. Laukkarinen et al.
Notes: Centralization influences long‐term survival
Systematic review of transarterial embolization for hepatocellular adenomas. BJS 2017; 104: 823-835.
Authors: B. V. van Rosmalen, R. J. S. Coelen, M. Bieze, O. M. van Delden, J. Verheij, C. H. C. Dejong et al.
Notes: Safe alternative to surgery
Authors: T. Ebata, T. Mizuno, Y. Yokoyama, T. Igami, G. Sugawara, M. Nagino et al.
Notes: irresectability revisited
Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. BJS 2017; 104: 1045-1052.
Authors: H. Kim, S. W. Ahn, S. K. Hong, K. C. Yoon, H.‐S. Kim, Y. R. Choi et al.
Notes: Selected patients benefit
Accuracy of circulating histones in predicting persistent organ failure and mortality in patients with acute pancreatitis.
Authors: T. Liu, W. Huang, P. Szatmary, S. T. Abrams, Y. Alhamdi, Z. Lin et al.
Notes: Potential as early prediction biomarker
Dual hypothermic oxygenated machine perfusion in liver transplants donated after circulatory death. BJS 2017; 104: 907-917.
Authors: R. van Rijn, N. Karimian, A. P. M. Matton, L. C. Burlage, A. C. Westerkamp, A. P. van den Berg et al.
Notes: Increases donor pool
Prospective trial to evaluate the prognostic value of different nutritional assessment scores in pancreatic surgery (NURIMAS Pancreas). BJS 2017; 104: 1053-1062.
Authors: P. Probst, S. Haller, T. Bruckner, A. Ulrich, O. Strobel, T. Hackert et al.
Notes: No score of use
Authors: F. J. Hüttner, P. Probst, P. Knebel, O. Strobel, T. Hackert, A. Ulrich et al.
Notes: No benefit
Prognostic impact of margin status in liver resections for colorectal metastases after bevacizumab. BJS 2017; 104: 926-935.
Authors: K. Sasaki, G. A. Margonis, N. Andreatos, A. Wilson, M. Weiss, C. Wolfgang et al.
Notes: Antiangiogenesis antibody of benefit
Impact of hepatobiliary service centralization on treatment and outcomes in patients with colorectal cancer and liver metastases. BJS 2017; 104: 918-925.
Authors: A. E. Vallance, J. vanderMeulen, A. Kuryba, I. D. Botterill, J. Hill, D. G. Jayne et al.
Notes: Better survival
Liver transection using indocyanine green fluorescence imaging and hepatic vein clamping. BJS 2017; 104: 898-906.
Authors: Y. Kawaguchi, Y. Nomura, M. Nagai, D. Koike, Y. Sakuraoka, T. Ishida et al.
Notes: To see or not to see
Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. BJS 2017; 104: 760-768.
Authors: B. C. Odisio, S. Yamashita, S. Y. Huang, S. Harmoush, S. E. Kopetz, K. Ahrar et al.
Notes: Mutant RAS poor prognostic factor